Kraematon Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

Kraematon Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,815	Closed	-$220K	–	88
2024 Q2	$220K	Hold	9,815	–	–	0.22%	78
2024 Q1	$270K	Sell	9,815 -875	-8%	-$24.3K	0.27%	73
2023 Q4	$326K	Sell	10,690 -840	-7%	-$24.1K	0.36%	64
2023 Q3	$365K	Sell	11,530 -1,000	-8%	-$38.8K	0.45%	56
2023 Q2	$511K	Buy	12,530 +4,150	+50%	+$168K	0.56%	52
2023 Q1	$312K	Buy	8,380 +2,750	+49%	+$108K	0.36%	61
2022 Q4	$196K	Sell	5,630 -160	-3%	-$7.61K	0.21%	83
2022 Q3	$324K	Sell	5,790 -350	-6%	-$21.7K	0.42%	59
2022 Q2	$318K	Hold	6,140	–	–	0.37%	60
2022 Q1	$446K	Buy	6,140 +15	+0.2%	+$1.27K	0.42%	58
2021 Q4	$724K	Buy	+6,125	New	+$767K	0.65%	44

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kraematon Investment Advisors's NTLA Position: Q3 2024 in Review

Kraematon Investment Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 9,815 shares — an estimated $220K sold.

Kraematon Investment Advisors first reported a position in NTLA in Q4 2021 and held it in 11 quarters. The position peaked at $724K in Q4 2021. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

Kraematon Investment Advisors reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
Kraematon Investment Advisors sold 9,815 Intellia Therapeutics shares in Q3 2024, an estimated $220K.
Kraematon Investment Advisors first reported a position in Intellia Therapeutics in Q4 2021 and held it in 11 quarters.
Kraematon Investment Advisors's Intellia Therapeutics position peaked at $724K in Q4 2021.
283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Kraematon Investment Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.